Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Intensity Modulated Total Marrow Irradiation (IMTMI) in Addition to Fludarabine/Melphalan Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies

NCT02333162 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT02333162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02333162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Intensity Modulated Total Marrow Irradiation (IMTMI) in Addition to Fludarabine/Melphalan Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
Lead sponsor
University of Chicago
Phase
Phase 1
Overall status
Suspended
Start date
December 5, 2014
Completion date
December 1, 2028
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

previously treated myelodysplastic syndrome, recurrent adult acute lymphoblastic leukemia, recurrent adult acute myeloid leukemia, recurrent hematologic malignancy